Skip to main content
. 2017 Oct 25;108(12):2495–2502. doi: 10.1111/cas.13414

Figure 2.

Figure 2

Expression level of CXCL7 in peripheral blood cells was upregulated in renal cell carcinoma (RCC) patients compared to healthy controls. (a) Expression level of CXCL7 in peripheral blood cells was quantified by quantitative RT‐PCR in the verification cohort (n = 180). **P < 0.01 (Wilcoxon test). (b) Comparison of the expression level of CXCL7 in peripheral blood cells among healthy controls, early stage RCC patients, and late stage RCC patients. **P < 0.01 (Dunn's multiple comparison test). (c) Expression level of CXCL7 in peripheral blood cells from pT1a patients. **P < 0.01 (Wilcoxon test). (d) Receiver operating characteristic curve analysis for the diagnosis of RCC using the expression level of CXCL7 in peripheral blood cells from the verification cohort (n = 180).